# NCT03386513 (NCT03386513)

> Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03386513
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AbbVie
- Conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm; Myeloproliferative Neoplasm
- Interventions: IMGN632
- Enrollment: 179
- Primary outcome: Composite Complete Remission/Response (CCR) Rate As Assessed by Investigator in Frontline De Novo Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Participants

## Indexed commentary on NCT03386513 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03386513